Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2010 - 2026)

Abeona Therapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 45.43% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (down 45.43% YoY), while the FY2025 annual figure was $18.9 million, down 40.96% from the prior year.
• Other Non-Current Liabilities was $13.5 million for Q1 2026 at Abeona Therapeutics, down from $18.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $48.7 million in Q1 2024 to a low of $200000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $19.9 million across 5 years, with a median of $22.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities soared 13461.0% in 2023, then sank 95.94% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $19.7 million in 2022, then soared by 59.5% to $31.4 million in 2023, then advanced by 2.11% to $32.0 million in 2024, then slumped by 40.96% to $18.9 million in 2025, then slipped by 28.49% to $13.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $13.5 million (Q1 2026), $18.9 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.